BCYC: רווח למניה בשנים עשר החודשים האחרונים bicycletherapeutics.com

Bicycle Therapeutics (BCYC) develops highly selective targeted drugs based on unique peptides. The company's annual net profit per share in the time series on the GURU.Markets chart correlates with payments from pharma behemoths, while the -2.02 indicator determines the parameter status. Revenues are based on royalties from platform licensing, while the asset's market value relies on interim partner payments.
Bicycle Pharma (BCYC) - פילוחי מדדים ודוחות פיננסיים

This indicator measures the real yield of each share by dividing the total net income over a rolling year by the total number of securities outstanding. By analyzing the 12-month net income per share chart, an investor can track the impact of geopolitical risks and peptide logistics disruptions on the financial stability of Bicycle Therapeutics (BCYC).